|
|
Volumn 3, Issue 3, 2007, Pages 130-131
|
|
Is anti-TNF theraphy safe in patients with rheumatic disease who also have concurrent B or C chronic hepatitis? Commentary
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
ALANINE AMINOTRANSFERASE;
ASPARTATE AMINOTRANSFERASE;
CORTICOSTEROID;
ETANERCEPT;
HEPATITIS B SURFACE ANTIGEN;
LAMIVUDINE;
METHOTREXATE;
TUMOR NECROSIS FACTOR ANTIBODY;
ALANINE AMINOTRANSFERASE BLOOD LEVEL;
ASPARTATE AMINOTRANSFERASE BLOOD LEVEL;
COMORBIDITY;
DATA ANALYSIS;
DRUG CONTRAINDICATION;
DRUG EFFICACY;
DRUG SAFETY;
DRUG SUBSTITUTION;
DRUG WITHDRAWAL;
HEPATITIS B;
HEPATITIS B VIRUS;
HEPATITIS C;
HEPATITIS C VIRUS;
HUMAN;
IMMUNE DEFICIENCY;
LIVER CIRRHOSIS;
PATIENT MONITORING;
PRIORITY JOURNAL;
RHEUMATIC DISEASE;
RHEUMATOID ARTHRITIS;
RISK ASSESSMENT;
SHORT SURVEY;
SIDE EFFECT;
SPONDYLOARTHROPATHY;
TREATMENT DURATION;
TREATMENT OUTCOME;
VIRUS LOAD;
|
|
EID: 33947238984
PISSN: 17458382
EISSN: 17458390
Source Type: Journal
DOI: 10.1038/ncprheum0403 Document Type: Short Survey |
|
Times cited : (3)
|
|
References (5)
|
